**Abstract**

The *MBD5* gene has been widely cited as a risk gene for neurodevelopmental features. Both partial and complete deletions of *MBD5* involving coding and/or non-translated exons are resulted in autism spectrum disorders (ASD), intellectual disability and epilepsy. A significant excess of a rare single nucleotide variant (SNV) in *MBD5* coding exon have been detected in ASD patients. The phenotypes observed in patients having disruption of *MBD5* include autistic-like symptoms, developmental delay, behavioral problems, repetitive behaviors and seizures. The aim of the present study was to investigate the association between rare *MBD5* variants and neuropsychiatric pathogenesis.

A total of 192 ASD (mean age ± SD = 16.3 ± 8.4 years; 77.6% male) and 370 schizophrenia (mean age ± SD, 49.7 ± 14.8 years; 53.0% male) individuals participated. First, we conducted exon-targeted resequencing of *MBD5* with next-generation sequencing technology in 562 Japanese patients and detected 12 rare missense variants. We compared phenotypes of patients having these variants with the core characteristics associated with *MBD5* SNVs, but no typical characteristics have been observed. Although rare SNVs in *MBD5* identified in our study may not have marked impact on the neurodevelopmental features, the exact molecular mechanisms and networks affected by *MBD5* variants in SCZ and ASD remain unclear. Useful model systems that can address these questions will be needed to assess the impact of the SNVs discovered here. This study is important to understand the burden of rare SNVs in *MBD5*.

All procedures performed in this study involving human participants were approved by the Ethics Committee of the Nagoya University Graduate School of Medicine and conducted in accordance with the Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from the participants and from the parents of the patients under 20 years old.
